Johnson & Johnson (NYSE:JNJ) Stock Acquired Rep. Lloyd Doggett

Representative Lloyd Doggett (D-Texas) recently bought shares of Johnson & Johnson (NYSE:JNJ). In a filing disclosed on January 02nd, the Representative disclosed that they had bought between $1,001 and $15,000 in Johnson & Johnson stock on December 9th.

Representative Lloyd Doggett also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 12/18/2025.
• Purchased $1,001 – $15,000 in shares of CocaCola (NYSE:KO) on 12/15/2025.
• Purchased $1,001 – $15,000 in shares of PPG Industries (NYSE:PPG) on 12/12/2025.
• Purchased $1,001 – $15,000 in shares of International Business Machines (NYSE:IBM) on 12/12/2025.

Johnson & Johnson Stock Down 1.5%

Shares of Johnson & Johnson stock opened at $204.32 on Tuesday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The firm has a market cap of $492.26 billion, a price-to-earnings ratio of 19.72, a P/E/G ratio of 2.13 and a beta of 0.34. The stock has a 50-day simple moving average of $201.45 and a 200-day simple moving average of $183.45. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $215.18.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The firm had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. On average, equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s payout ratio is currently 50.19%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in JNJ. Abich Financial Wealth Management LLC bought a new position in Johnson & Johnson during the 3rd quarter worth $26,000. Clayton Financial Group LLC bought a new position in Johnson & Johnson during the third quarter valued at about $28,000. Evolution Wealth Management Inc. purchased a new position in shares of Johnson & Johnson during the 2nd quarter valued at $27,000. Semmax Financial Advisors Inc. raised its holdings in Johnson & Johnson by 55.0% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after acquiring an additional 72 shares during the period. Finally, Turning Point Benefit Group Inc. purchased a new stake in shares of Johnson & Johnson in the third quarter worth about $41,000. Institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on JNJ. Sanford C. Bernstein upped their price target on Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a research report on Monday, October 6th. HSBC restated a “buy” rating and issued a $240.00 price target on shares of Johnson & Johnson in a research report on Wednesday, December 10th. Bank of America lifted their price target on shares of Johnson & Johnson from $204.00 to $220.00 and gave the stock a “neutral” rating in a research report on Monday, December 15th. Cowen reissued a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, October 14th. Finally, Raymond James Financial boosted their target price on Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research note on Wednesday, October 15th. Four research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $212.62.

About Representative Doggett

Lloyd Doggett (Democratic Party) is a member of the U.S. House, representing Texas’ 37th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Doggett (Democratic Party) is running for re-election to the U.S. House to represent Texas’ 37th Congressional District. He declared candidacy for the 2026 election.

Lloyd Doggett was born in Austin, Texas. Doggett graduated from Austin High School in 1964. He earned a B.A. from the University of Texas at Austin in 1967 and a J.D. from the University of Texas in 1970. Doggett’s career experience includes working as an adjunct professor with the University of Texas School of Law. In the 116th Congress, Doggett served on the House Ways & Means Committee, and he co-founded the House Prescription Drug Taskforce.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.